Related Experiment Video
Updated: Jun 17, 2025
Predictive Immune Modeling of Solid Tumors
Published on: February 25, 2020
Mathematical Modeling of Tumor Immune Interactions: The Role of Anti-FGFR and Anti-PD-1 in the Combination Therapy
Chenghang Li1, Zonghang Ren1, Guiyu Yang2
1School of Mathematical Sciences, Tiangong University, Tianjin, 300387, China.
Abstract:
Bladder cancer poses a significant global health burden with high incidence and recurrence rates. This study addresses the therapeutic challenges in advanced bladder cancer, focusing on the competitive mechanisms of ligand or drug binding to receptors. We developed a refined mathematical model that integrates the dynamics of tumor cells and immune responses, particularly targeting fibroblast growth factor receptor 3 (FGFR3) and immune checkpoint inhibitors (ICIs). This study contributes to understanding combination therapies by elucidating the competitive binding dynamics and quantifying the synergistic effects. The findings highlight the importance of personalized immunotherapeutic strategies, considering factors such as drug dosage, dosing schedules, and patient-specific parameters. Our model further reveals that ligand-independent activated-state receptors are the most essential drivers of tumor proliferation. Moreover, we found that PD-L1 expression rate was more important than PD-1 in driving the dynamic evolution of tumor and immune cells. The proposed mathematical model provides a comprehensive framework for unraveling the complexities of combination therapies in advanced bladder cancer. As research progresses, this multidisciplinary approach contributes valuable insights toward optimizing therapeutic strategies and advancing cancer treatment paradigms.
Insights
This study models advanced bladder cancer treatments, revealing ligand-independent receptors drive proliferation. It highlights PD-L1's importance over PD-1 in tumor-immune dynamics for personalized immunotherapy.
Area of Science:
- Oncology
- Mathematical Biology
- Immunology
Background:
- Bladder cancer presents significant global health challenges due to high incidence and recurrence rates.
- Therapeutic strategies for advanced bladder cancer face complexities, particularly concerning competitive receptor binding dynamics.
Purpose of the Study:
- To develop a mathematical model integrating tumor and immune dynamics for advanced bladder cancer.
- To investigate competitive binding mechanisms of fibroblast growth factor receptor 3 (FGFR3) and immune checkpoint inhibitors (ICIs).
- To elucidate synergistic effects and optimize combination immunotherapies.
Main Methods:
- Development of a refined mathematical model incorporating tumor cell and immune response dynamics.
- Analysis of competitive ligand/drug binding to receptors, focusing on FGFR3 and ICIs.
- Quantification of synergistic effects in combination therapies.
Main Results:
- Ligand-independent activated-state receptors were identified as key drivers of tumor proliferation.
- The PD-L1 expression rate was found to be more critical than PD-1 in influencing tumor and immune cell evolution.
- The model demonstrated the importance of personalized parameters like drug dosage and schedules.
Conclusions:
- The mathematical model offers a comprehensive framework for understanding advanced bladder cancer combination therapies.
- Findings underscore the need for personalized immunotherapeutic strategies tailored to patient-specific factors.
- This multidisciplinary approach provides insights for optimizing bladder cancer treatment paradigms.
Related Concept Videos
01:27Tumor Immunotherapy
02:17The Tumor Microenvironment